Greek prosecutors raid Novartis offices, disclose wide-ranging probe into bribery allegations

Novartis HQ cropped
Novartis says it is cooperating with "local and foreign" officials investigating corruption allegations in Greece.

Greek officials announced Tuesday that they are investigating Novartis for bribery in the wake of local media reports raising questions about the company. It is the fourth set of bribery allegations against the Swiss drugmaker to go public in the past year.

Greek authorities have interviewed scores of sources and raided Novartis offices in Greece, according to multiple local news outlets. Justice Minister Stavros Kontonis ordered the inquiry after "denunciations concerning bribes paid to functionaries by Novartis" appeared in the press, the ministry said in a statement, as quoted by Agence France Presse (AFP).

According to media reports in Greece, authorities announced the probe after a former Novartis manager in the country made suicide threats at an Athens hotel on New Year’s Day. Judicial sources told the Swiss news agency ATS that the man was among the company employees to be interviewed by prosecutors.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Novartis said in a statement that it is aware of the media reports about its business practices in Greece and is “actively seeking further information.”

The company is “fully cooperating with requests from local and foreign authorities,” the statement said. “Novartis is committed to the highest standards of ethical business conduct and regulatory compliance in all aspects of its work and takes any allegation of misconduct extremely seriously.”

Greek prosecutors have requested assistance from the U.S. government in their probe, the local news site Greek Reporter says. They say the U.S. is investigating similar allegations of bribery in Greece, apparently for violations of the U.S. Foreign Corrupt Practices Act.

"The judicial investigation will be swift and thorough," the ministry’s statement said.

Those original media reports also stated that two Novartis executives had been questioned by the U.S. Securities and Exchange Commission in August. The managers were said to have handed over hundreds of documents to SEC officials detailing more than 4,000 payments to doctors, the Athens-Macedonian News Agency said Tuesday.

Greece’s investigation follows a similar probe launched in South Korea last February and corruption allegations leveled by a Turkish whistleblower in March. In August, South Korean prosecutors indicted a half-dozen Novartis executives for issuing improper rebates to local doctors.

Also last year, Novartis agreed to pay $25 million to settle an SEC investigation into bribery allegations in China. According to the SEC, Novartis offered Chinese doctors lavish entertainment—including a junket to Chicago and Niagara Falls—and other inducements to boost prescriptions of its drugs in the country.

Novartis is not the only multinational drugmaker paying fines to the U.S. for foreign corruption. AstraZeneca agreed last year to pay $5.5 million to settle the SEC’s allegations of bribery in China. And in a settlement that dwarfs all the others, Israel-based generics giant Teva agreed last month to hand over $520 million to wrap up a raft of bribery allegations in Russia, Ukraine and Mexico, the largest-ever FCPA settlement for a drugmaker.

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.